![A calculator based on prostate imaging reporting and data system version 2 (PI-RADS V2) is a promising prostate cancer predictor | Scientific Reports A calculator based on prostate imaging reporting and data system version 2 (PI-RADS V2) is a promising prostate cancer predictor | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-019-43427-9/MediaObjects/41598_2019_43427_Fig1_HTML.png)
A calculator based on prostate imaging reporting and data system version 2 (PI-RADS V2) is a promising prostate cancer predictor | Scientific Reports
![Cancers | Free Full-Text | Comparison of Proclarix, PSA Density and MRI-ERSPC Risk Calculator to Select Patients for Prostate Biopsy after mpMRI Cancers | Free Full-Text | Comparison of Proclarix, PSA Density and MRI-ERSPC Risk Calculator to Select Patients for Prostate Biopsy after mpMRI](https://pub.mdpi-res.com/cancers/cancers-14-02702/article_deploy/html/images/cancers-14-02702-g001-550.jpg?1653911161)
Cancers | Free Full-Text | Comparison of Proclarix, PSA Density and MRI-ERSPC Risk Calculator to Select Patients for Prostate Biopsy after mpMRI
![Can Western Based Online Prostate Cancer Risk Calculators Be Used to Predict Prostate Cancer after Prostate Biopsy for the Korean Population? Can Western Based Online Prostate Cancer Risk Calculators Be Used to Predict Prostate Cancer after Prostate Biopsy for the Korean Population?](https://www.eymj.org/ArticleImage/0069YMJ/ymj-54-665-i001-l.jpg)
Can Western Based Online Prostate Cancer Risk Calculators Be Used to Predict Prostate Cancer after Prostate Biopsy for the Korean Population?
![Avoiding Unnecessary Biopsy: MRI-based Risk Models versus a PI-RADS and PSA Density Strategy for Clinically Significant Prostate Cancer | Radiology Avoiding Unnecessary Biopsy: MRI-based Risk Models versus a PI-RADS and PSA Density Strategy for Clinically Significant Prostate Cancer | Radiology](https://pubs.rsna.org/cms/10.1148/radiol.2021204112/asset/images/medium/radiol.2021204112.va.gif)
Avoiding Unnecessary Biopsy: MRI-based Risk Models versus a PI-RADS and PSA Density Strategy for Clinically Significant Prostate Cancer | Radiology
![Prostate-specific Antigen Density Cutoff of 0.15 ng/ml/cc to Propose Prostate Biopsies to Patients with Negative Magnetic Resonance Imaging: Efficient Threshold or Legacy of the Past? - European Urology Focus Prostate-specific Antigen Density Cutoff of 0.15 ng/ml/cc to Propose Prostate Biopsies to Patients with Negative Magnetic Resonance Imaging: Efficient Threshold or Legacy of the Past? - European Urology Focus](https://www.eu-focus.europeanurology.com/cms/attachment/f88739ff-71c0-4bf0-935f-361ae3f12d77/gr1_lrg.jpg)
Prostate-specific Antigen Density Cutoff of 0.15 ng/ml/cc to Propose Prostate Biopsies to Patients with Negative Magnetic Resonance Imaging: Efficient Threshold or Legacy of the Past? - European Urology Focus
![Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer | Prostate Cancer and Prostatic Diseases Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer | Prostate Cancer and Prostatic Diseases](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41391-017-0024-7/MediaObjects/41391_2017_24_Fig1_HTML.jpg)